MBX Biosciences (MBX) EPS (Basic) (2023 - 2026)

MBX Biosciences has reported EPS (Basic) for 4 years, with the latest figure at -$0.5 in Q1 2026.

• Quarterly EPS (Basic) rose 29.35% year-over-year to -$0.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.86 (up 15.43% YoY) and the FY2025 annual result came in at -$2.38, up 59.05% from the prior year.
• EPS (Basic) improved to -$0.5 in Q1 2026 per MBX's latest filing, from -$0.6 in the prior quarter.
• Over five years, EPS (Basic) peaked at -$0.5 in Q1 2026 and troughed at -$12.62 in Q2 2024.
• A 4-year average of -$4.39 and a median of -$1.46 in 2024 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2025 and 2026: EPS (Basic) surged 95.4% in 2025, then climbed 29.35% in 2026.
• Over 4 years, EPS (Basic) stood at -$8.68 in 2023, then soared by 83.13% to -$1.46 in 2024, then jumped by 58.73% to -$0.6 in 2025, then grew by 16.45% to -$0.5 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.5, -$0.6, and -$0.63 for Q1 2026, Q4 2025, and Q3 2025 respectively.